KRAS and pancreatic neoplasm: For instance, noticeable discordance exists among different populations: the KRAS mutation rate reached 94% in a pancreatic intraepithelial neoplasm population 73, whereas it was only 30% in a population involving 221 patients with surgically resectable pancreatic cancer patients, and ctDNA-CP integration merely increased the sensitivity to 64% 8.